OptimizeRx Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$OPRX
Business Services
Consumer Discretionary
Get the next $OPRX alert in real time by email

Weekly insight reads limit reached.

Join Quantisnow to enjoy unlimited reads, alerts, live feeds, and more.

Meet Quantisnow

Stock alerts. Live news feeds. Press releases. Insider trading. FDA approvals & more.

Invest smarter

A better trading workflow

Access market-moving news before they break out to the general public. Let Quantisnow cut out the noise and only receive insights that matter.

Live feeds
Real-time news feeds for Press Releases, SEC Filings, FDA approvals, market insights and more.
Custom filters
Filter out the noise with company filters, market cap filters, price filters and more.
Audio Squawk
Multitask with confidence and let Quantsinow read breaking news out loud.
Product screenshot
Quantisnow AI Features

Save time

Unlock Insights with AI

Get quick summaries and precise Q&A for every insight, empowering you to make informed decisions without sifting through entire press releases and lengthy SEC filings.

Get alerted immediately

All your stock market alerts in one place

Quantisnow alerts are fast, customizable, and versatile.

Email alerts
Subscribe to your favorite stocks and receive email alerts each time a news pops up.
App notifications
Reduce alerting latency with in-app notifications. Same as email alerts, but faster.
Webhooks
Integrate with Quantisnow programmatically and receive live insights via webhooks
Granular alerts
Want to receive Press Releases but no SEC filings? No problem - Quantisnow alerts are highly customizable and can seemlessly tailor to your trading needs.

Elevate your trading.
Start using Quantisnow today.

Never miss an update.

App screenshot

Simple no-tricks pricing

One membership with full access and no delays.

Quantisnow Plus

Your personal trading assistant for just $39/month.

What's included

  • Live feeds
  • Audio squawk
  • Compact mode in feeds
  • Email alerts
  • App push alerts
  • Unlimited insights reads
  • Unlimited subscriptions
  • Advanced filters in live feeds
  • Support
  • No ads
  • AI-generated summaries and Q&A

One membership - all access

$39/month

Get access

$39/month with yearly billing, $49/month with monthly billing

News insights ingested and delivered in real time
5 million+
Real-time news alerts sent out to Quantisnow users
700,000+
Latency of news delivery pipelines to users via mobile app, webhooks, and email
<100ms
Get the next $OPRX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$OPRX

DatePrice TargetRatingAnalyst
1/8/2025$7.00 → $6.00Outperform → Sector Perform
RBC Capital Mkts
12/20/2024$5.50Equal-Weight
Stephens
7/25/2024$18.50Buy
B. Riley Securities
4/4/2024$15.00Mkt Outperform
JMP Securities
1/3/2024$15.00Equal Weight
Barclays
2/2/2023$30.00Buy
B. Riley Securities
11/1/2022$19.00Buy
Stifel
7/15/2022$38.00Outperform
SVB Leerink
More analyst ratings

$OPRX
Press Releases

Fastest customizable press release news feed in the world

See more
  • OptimizeRx Reports Strong Fourth Quarter and Full Year 2024 Financial Results

    Q4 revenue of $32.3 million, increasing 14% year-over-yearQ4 gross profit increased 23% year-over-year to $22.0 million with gross margin of 68%Company generated revenue from 48 DAAP deals in 2024, up from 24 in 2023 WALTHAM, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced results for the fourth quarter and full year ended December 31, 2024.  For the Year EndedDecember 31,Key Performance Indicators (KPIs)* 2024   2023  (in thousands, except percentages)Average revenue per top 20 pharma

    $OPRX
    Business Services
    Consumer Discretionary
  • OptimizeRx Corporation Confirms Receipt of Notice of Director Nominations

    WALTHAM, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today confirmed that it has received a purported notice of nominations from a stockholder, Whetstone Capital Advisors, LLC, regarding its intention to nominate two candidates for election to the OptimizeRx Board of Directors at the Company's 2025 Annual Meeting of Stockholders. The OptimizeRx Board of Directors will make its formal recommendation regarding director nominations in the Company's definitive proxy statement which will be filed w

    $OPRX
    Business Services
    Consumer Discretionary
  • OptimizeRx Corporation Appoints Stephen Silvestro as Chief Executive Officer

    WALTHAM, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced it has appointed Steve Silvestro as the Company's new Chief Executive Officer, effective March 10, 2025. Mr. Silvestro brings to OptimizeRx more than 20 years of experience in building and managing health technology and services companies, and has served as an executive at OptimizeRx since joining the Company in 2019. His career includes strategic development, sales leadership, technology and product innovation, and M&A within a

    $OPRX
    Business Services
    Consumer Discretionary

$OPRX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$OPRX
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$OPRX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$OPRX
SEC Filings

See more

$OPRX
Leadership Updates

Live Leadership Updates

See more
  • OptimizeRx Corporation Appoints Stephen Silvestro as Chief Executive Officer

    WALTHAM, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced it has appointed Steve Silvestro as the Company's new Chief Executive Officer, effective March 10, 2025. Mr. Silvestro brings to OptimizeRx more than 20 years of experience in building and managing health technology and services companies, and has served as an executive at OptimizeRx since joining the Company in 2019. His career includes strategic development, sales leadership, technology and product innovation, and M&A within a

    $OPRX
    Business Services
    Consumer Discretionary
  • OptimizeRx Announces Departure of CEO William Febbo and Appointment of Stephen Silvestro as Interim CEO

    WALTHAM, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that William J. Febbo, Chief Executive Officer (CEO) and Board Member, will be departing the Company, effective as of December 31, 2024, to pursue other opportunities. Mr. Febbo will provide the Company with advisory services through March 31, 2025. The Company's Board of Directors has retained a search firm to assist in this transition. "The time is right to pass the reins on to an incredible team, ready to carry the legacy forwa

    $OPRX
    Business Services
    Consumer Discretionary
  • OptimizeRx Announces Strategic Board Changes to Support Growth and Evolving Landscape

    WALTHAM, Mass., Jan. 25, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, is pleased to announce changes to its Board of Directors reflecting a strategic move to further align with the company's growth plans. After nearly a decade of service, Gus Halas is retiring from his position as Chairperson of the Board. During his tenure, he played a pivotal role in shaping OptimizeRx's success, and we extend our deepest gratitude for his commitment and leadership. Effective immediately, Lynn O'Connor Vos will assume the role o

    $AWH
    $OPRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Business Services
    Consumer Discretionary

$OPRX
Financials

Live finance-specific insights

See more
  • OptimizeRx Reports Strong Fourth Quarter and Full Year 2024 Financial Results

    Q4 revenue of $32.3 million, increasing 14% year-over-yearQ4 gross profit increased 23% year-over-year to $22.0 million with gross margin of 68%Company generated revenue from 48 DAAP deals in 2024, up from 24 in 2023 WALTHAM, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced results for the fourth quarter and full year ended December 31, 2024.  For the Year EndedDecember 31,Key Performance Indicators (KPIs)* 2024   2023  (in thousands, except percentages)Average revenue per top 20 pharma

    $OPRX
    Business Services
    Consumer Discretionary
  • OptimizeRx Sets Fourth Quarter and Full Year 2024 Financial Results Conference Call for March 12, 2025, at 8:30 a.m. ET

    WALTHAM, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, will hold a conference call on Wednesday, March 12, 2025, at 8:30 a.m. Eastern Time to discuss full year fiscal 2024 financial results and the fourth quarter period ended December 31, 2024. The financial results will be issued in a press release prior to the call. OptimizeRx management will host the call, followed by a question-and-answer period. Details for the conference call can be found below: Date:Wednesday, March 12, 2025Time:8:30 a.m. Easte

    $OPRX
    Business Services
    Consumer Discretionary
  • OptimizeRx Reports Third Quarter 2024 Financial Results

    - Q3 revenue of $21.3 million, increasing 30% year-over-year - Q3 gross profit increased 37% year-over-year to $13.4 million with a gross margin of 63% - Won 5 DAAP deals during Q3 WALTHAM, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, reported results for the three months ended September 30, 2024. Quarterly comparisons are to the same year-ago period. Financial Highlights Revenue in the third quarter of 2024 increased 30% to $21.3 million, as compared to $

    $OPRX
    Business Services
    Consumer Discretionary

$OPRX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more